Sponsor Deadline
Posted: 4/18/2022

Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed)

The purpose of this FOA is to solicit applications for the development of novel, untested analytics and technologies to identify and map senescent cells in human tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

While SenNet is currently focused on human tissues, efforts are now underway to incorporate murine Tissue Mapping Centers and murine Technology Development Projects into SenNet with a framework and goals consistent with those currently in place for the human. These efforts related to murine cellular senescence will be funded with the companion FOAs: RFA-RM-22-003 and RFA-RM-22-005.


  • Letter of Intent Due Date(s): Dec. 20, 2021

  • Application Due Date(s): Jan. 19, 2022

RFA-RM-22-004 Expiration Date January 20, 2022

Eligibility Requirements

An investigator designated as the Contact PD/PI or MPI of an application under this FOA must not be the designated Contact PD/PI of any currently funded RFA-RM-21-008; RFA-RM-21-009, RFA-RM-21-010 or any of the companion SenNet FOAs RFA-RM-22-003 and RFA-RM-22-005.

Amount Description

Applications should not exceed $400,000 in direct costs per year during the UG3 phase and $550,000 in direct costs per year during the UH3 phase.